Skip to content

Gemeprost Versus Dinoprostone in First Trimester Miscarriages

Gemeprost Versus Dinoprostone in the Medical Management of First Trimester Miscarriages: a Randomized Controlled Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05342467
Enrollment
101
Registered
2022-04-22
Start date
2022-11-11
Completion date
2024-10-28
Last updated
2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete Abortion, Medical; Abortion, Fetus, Missed Abortion

Keywords

miscarriages, first trimester, medical treatment

Brief summary

Comparison between gemeprost and dinoprostone to evacuate first trimester miscarriages.

Detailed description

Women who are diagnosed with first trimester missed miscarriages are invited to participate in the study. They will be randomised to either gemeprost or dinoprostone.

Interventions

DRUGGemeprost 1 Mg Vaginal Pessary

Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours

Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours

Sponsors

National University of Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Comparison between intravaginal gemeprost and dinoprostone.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* missed miscarriages * incomplete miscarriages * first trimester

Exclusion criteria

* coagulopathy * Rhesus negative * suspected ectopic pregnancy or pregnancy of unknown location * on anticoagulation drug * septic miscarriages * hemodynamically unstable

Design outcomes

Primary

MeasureTime frameDescription
Percentage of women who achieved complete evacuationfrom recruitment until up to one week after commencement of treatmentComplete expulsion of product of conception

Secondary

MeasureTime frameDescription
Percentage of women who experienced side effectsfrom recruitment until up to one week after commencement of treatmentside effects towards each drug such as fever, gastrointestinal upset

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026